Forward Pharma A/S Stock News

Forward Pharma A/S (NASDAQ:FWP) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 73,100 shares, a drop of 31.0% from the November 15th total of 105,900 shares. Approximately 1.1% of the shares of the company are short sold. Based on []

Forward Pharma A/S (NASDAQ:FWP) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 105,900 shares, a growth of 39.5% from the October 31st total of 75,900 shares. Currently, 1.6% of the companys stock are sold short. Based on an average []

Forward Pharma A/S (NASDAQ:FWP) saw a large drop in short interest in October. As of October 29th, there was short interest totalling 75,900 shares, a drop of 29.1% from the October 14th total of 107,000 shares. Based on an average daily trading volume, of 133,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.1% []

Shares of Forward Pharma A/S (NASDAQ:FWP) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $6.76 and traded as high as $6.77. Forward Pharma A/S shares last traded at $6.58, with a volume of 19,400 shares. The business has a fifty day simple []

Forward Pharma A/S (NASDAQ:FWP) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $6.94 and traded as low as $6.62. Forward Pharma A/S shares last traded at $6.85, with a volume of 31,517 shares trading hands. The business’s 50-day moving average is […]

Forward Pharma A/S (NASDAQ:FWP) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 107,000 shares, a growth of 47.6% from the September 30th total of 72,500 shares. Approximately 1.6% of the companys stock are short sold. Based on an average daily trading volume, []

BVF Inc. IL decreased its stake in shares of Forward Pharma A/S (NASDAQ:FWP) by 18.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 528,514 shares of the biotechnology companys stock after selling 118,785 shares during the period. BVF Inc. IL owned about 7.67% of Forward []

The stock price of Forward Pharma A/S (NASDAQ: FWP ) fell by almost 20% during the premarket. Investors are responding negatively to the Technical Board of Appeal (TBA) of the European Patent Office (EPO), dismissing Forwards appeal to revoke the EP2801355 Full story available on Benzinga.com

The stock price of Forward Pharma A/S (NASDAQ: FWP) fell by almost 20% during the premarket.  Investors are responding negatively to the Technical Board of Appeal (TBA) of the European Patent Offic

The stock price of Forward Pharma A/S (NASDAQ:FWP) fell by over 20% pre-market. This is why it happened.

COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.

COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA�

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced new preclinical data for its lead drug candidate atuzaginstat in periodontal disease) Intuitive Surgical, Inc. (NASDAQ: ISRG ) (reacted to better-than-expected second-quarter results) Forward Pharma A/S (NASDAQ: FWP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 21) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Cyteir Therapeutics, Inc. (NASDAQ: CYT ) Elevation Oncology, Inc. (NASDAQ: ELEV ) Ensysce Biosciences, Inc. (NASDAQ: ENSC ) ERYTECH Pharma S.A. (NASDAQ: ERYP ) HCW Biologics Inc. (NASDAQ: HCWB ) (IPOed Tuesday) Lumos Pharma, Inc. (NASDAQ: LUMO ) ( signaled a delay in clinical trials of its treatment for pediatric growth deficiency) Medicenna Therapeutics Corp. (NASDAQ: MDNA ) Nautilus Biotechnology, Inc. (NASDAQ: NAUT ) OptiNose, Inc. (NASDAQ: OPTN ) POINT Biopharma Global Inc. (NASDAQ: PNT ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) (IPOed Friday) VectivBio Holding AG (NASDAQ: VECT ) Yumanity Therapeutics, Inc. (NASDAQ: YMTX ) Stocks In Focus Erytech Plans Regulatory Submission For Eryaspase In Blood Cancer Following Positive Pre-BLA Meeting Erytech said it intends to move forward toward the submission of a biologic license application to the U.S.